Hikal's Q4 profit sinks under ₹47 cr write-down; no FY27 guidance
Operating margins improved to 20.3% but a plant impairment and a USFDA warning letter are overshadowing the recovery.
— 4 earlier stories on Hikal Ltd. →What's new
- Q4 revenue was ₹519 cr with EBITDA margin at 20.3%, but net profit fell to ₹14.4 cr after a ₹47 cr impairment.
- FY26 revenue dropped 8% to ₹1,713 cr, and the company posted a full-year net loss due to exceptional items.
- A USFDA warning letter at the Bangalore facility has slowed shipments and muted near-term growth.
Why this matters
The impairment on a repurposed plant and the FDA warning letter are the real headlines, not the operating margin. The company is declining to guide for FY27, which signals management itself lacks visibility on when the pharma business will fully recover.
What we're watching
- Resolution of the USFDA warning letter and the pace of shipment recovery from Bangalore.
- Whether pharma capacity utilization can push past 85%.
- Any updated FY27 outlook once the plant repurposing is complete.
The full read
Hikal's Q4 numbers look tidy at first glance: ₹519 crore revenue and 20.3% EBITDA margins. But the ₹47 crore impairment charge on a repurposed manufacturing plant left net profit at just ₹14.4 crore. For the full year, revenue fell 8% to ₹1,713 crore, and the company swung to a net loss on exceptional items. The crop protection division is recovering as destocking eases, but the pharma business, the core of the company, is still dealing with a USFDA warning letter at its Bangalore facility that has slowed shipments. Capacity utilization in pharma improved to 80-85%, but management won't put a number on FY27, citing geopolitical uncertainty. The company says the worst of the operational challenges are behind it. The open question is whether FDA clearance and plant repurposing can deliver a real earnings uplift, not just a margin bounce.
Questions answered
- Why was Q4 net profit so low despite the margin improvement?
- The company took a ₹47 crore impairment charge related to repurposing a manufacturing plant. That exceptional item slashed net profit to ₹14.4 crore even as operating margins improved.
- How is the USFDA warning letter impacting operations?
- Management said the warning letter at the Bangalore facility has slowed shipments and is muting near-term growth. The company is still working through the compliance issues.
- What is the crop protection outlook?
- Inventory destocking has eased, and the division recovered in Q4. Management sees this as a positive sign, though the animal health CDMO business is still building toward long-term growth.
- Why won't management provide FY27 guidance?
- Executives declined to give specific revenue targets, citing geopolitical uncertainty. They expressed confidence that the worst of the operational challenges are behind them, but the lack of a number suggests a cautious near-term view.
Story so far
All notes on HIKAL →- 3 Jun 2026 · 5:26 PM IST Hikal's Q4 profit sinks under ₹47 cr write-down; no FY27 guidance
- 7d ago Hikal's earnings release adds no new data to prior disclosures.
- 7d ago Hikal's latest investor presentation adds no new information
- 7d ago Hikal fills key division vacancy and closes internal probe
- 7d ago Hikal swings to a loss as USFDA issues and impairments bite